
- Celltrion reported an operating profit of 242.47 billion won for the second quarter of 2025.
- This figure is an increase compared to last year’s 72.49 billion won, but it missed the estimated 253.59 billion won.
- The company’s sales increased by 9.9% year-on-year, reaching 961.46 billion won.
- Despite the increase, sales did not meet the estimate of 1.01 trillion won.
- Current analyst ratings for Celltrion include 24 buy recommendations, 3 holds, and 1 sell.
Celltrion Inc on Smartkarma
Analyst coverage of Celltrion Inc on Smartkarma reveals a bullish sentiment from top independent analysts. Tina Banerjee‘s report highlights Celltrion’s 1Q25 results, showing a sequential decrease in revenue but an improvement in gross profit margin. The company reaffirmed its 2025 revenue guidance of KRW5T, with expectations of stronger performance in 2H25.
In another report by Douglas Kim, the focus is on alpha generation through share buybacks in the Korean stock market. Kim discusses the impact of companies announcing share buybacks, with insights on the percentage of outstanding shares affected. The report suggests monitoring companies with significant share buyback announcements for potential trading opportunities.
A look at Celltrion Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts at Smartkarma have evaluated Celltrion Inc‘s long-term outlook using their Smart Scores system, which provides a comprehensive snapshot of the company’s performance across various key factors. The overall assessment reveals a mixed outlook for Celltrion Inc, with moderate scores in Value and Dividend at 2 each, signaling a fair valuation and dividend yield. However, the company excels in areas such as Growth with a score of 3, indicating promising prospects for expansion, and Resilience with a strong score of 4, suggesting a solid ability to weather market fluctuations. Momentum also shows a positive trend with a score of 3, hinting at potential upward movement.
Celltrion Inc, primarily known for its biosimilar products and consignment processing services, has a diversified portfolio with its flagship product, Abatacept, aimed at treating arthritis. With a balanced combination of strengths across different aspects of its operations, the company appears well-positioned to capitalize on growth opportunities while maintaining a resilient stance in the face of challenges, as reflected in its Smart Scores assessment.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
π‘ Before itβs here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- β Unlimited Research Summaries
- β Personalised Alerts
- β Custom Watchlists
- β Company Analytics and News
- β Events & Webinars